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ABSTRACT
Pharmacokinetic (PK) and pharmacodynamic (PD) principles that predict antimicrobial efﬁcacy can be
used to set targets for antimicrobial design and optimisation. Although current formulations of
amoxicillin and amoxicillin ⁄ clavulanate have retained their efﬁcacy against many, but not all, penicillin-
nonsusceptible Streptococcus pneumoniae, additional coverage is required to address the growing
problem of drug-resistant strains. Accordingly, two new oral formulations of amoxicillin ⁄ clavulanate, a
paediatric formulation at 90 ⁄ 6.4 mg ⁄ kg ⁄day and a pharmacokinetically enhanced formulation at
2000 ⁄ 125 mg twice daily for adults, were designed using PK ⁄PD principles. These principles indicate
that for amoxicillin and amoxicillin ⁄ clavulanate, a time above MIC of 35–40% of the dosing interval is
predictive of high bacterial efﬁcacy. In line with PK ⁄PD predictions, simulation of human pharmaco-
kinetics in in-vitro kinetic models and in a rat model of pneumonia, amoxicillin ⁄ clavulanate
2000 ⁄ 125 mg twice daily was highly effective against S. pneumoniae strains with amoxicillin MICs of
4 or 8 mg ⁄L. Against strains with amoxicillin MICs of 4 mg ⁄L, amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
twice daily was signiﬁcantly more effective than the conventional 875 ⁄ 125 mg twice daily formulation,
azithromycin and levoﬂoxacin, even though all levoﬂoxacin MICs were £ 1 mg ⁄L. Following infection
with S. pneumoniae strains with amoxicillin MICs of 8 mg ⁄L, the amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg
twice daily formulation was more effective than the conventional amoxicillin ⁄ clavulanate formulations
of 875 ⁄ 125 mg twice daily and three times daily and 1000 ⁄ 125 mg three times daily, and had similar or
better efﬁcacy than azithromycin and levoﬂoxacin, depending on the strain. These data indicate the
potential beneﬁt of therapy with amoxicillin ⁄ clavulanate 2000 ⁄ 125 mg twice daily compared with
conventional formulations and other marketed antimicrobials in the treatment of respiratory tract
infection.
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INTRODUCTION
The increasing frequency of antimicrobial resist-
ance in respiratory tract pathogens provides a
major challenge for the successful treatment of
pneumonia, sinusitis and other respiratory tract
infections. Amoxicillin ⁄ clavulanate at doses of
500 ⁄ 125 mg three times daily, 875 ⁄ 125 mg twice
or three times daily, or 1000 ⁄ 125 mg twice or
three times daily has proven to be a useful drug
for eradicating many of these resistant bacteria in
a variety of infections [1,2]. An array of studies
over the past decade has demonstrated that the
success of a speciﬁc dosing regimen is dependent
on the relationship between the extent of drug
exposure and the degree of drug susceptibility of
the infecting pathogen [3–5]. For drugs such
as amoxicillin and amoxicillin ⁄ clavulanate, the
important determinant is the duration of time
that serum concentrations exceed the MIC [6]. In
general, for amoxicillin ± clavulanate, serum con-
centrations should exceed the MIC for 35–40% of
the dosing interval to ensure antimicrobial efﬁc-
acy.
Over the past few years there has been a
gradual increase in the number of strains of
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Streptococcus pneumoniae with amoxicillin MICs of
4 and even 8 mg ⁄L [7]. Two new oral formula-
tions of amoxicillin ⁄ clavulanate, a paediatric for-
mulation of 90 ⁄ 6.4 mg ⁄ kg ⁄day in two divided
doses and a pharmacokinetically enhanced for-
mulation of 2000 ⁄ 125 mg twice daily for adults,
were developed to provide high drug concen-
trations that persist long enough to ensure
eradication of these high MIC strains [8,9]. The
paediatric formulation consists of a doubling of
the amoxicillin concentration used in conven-
tional amoxicillin ⁄ clavulanate in children. The
pharmacokinetically enhanced formulation con-
sists of a bilayer tablet containing a layer of
immediate-release amoxicillin ⁄ clavulanate and a
layer of sustained-release amoxicillin. Two tab-
lets provide a unit dose of 2000 ⁄ 125 mg of
amoxicillin ⁄ clavulanate that is administered
twice daily. Simulation of the high amoxicillin
concentrations produced by this formulation in
animal and in-vitro infection models should
provide useful data on the potential of this
new formulation for successfully treating high
MIC organisms in patients. This brief review will
(i) summarise the results of several in-vitro and
animal model studies using strains of S. pneu-
moniae with amoxicillin ⁄ clavulanate MICs of 4
and 8 mg ⁄L, and (ii) correlate outcome with the
duration of time for which drug concentrations
exceed the MIC of these pathogens.
IN-VITRO MODELS
In-vitro kinetic models have proven to be very
useful for determining the activity of human
simulated serum concentrations against a variety
of micro-organisms. Lo¨wdin, Cars and Odenholt
[10,11] have examined the activity of the new
pharmacokinetically enhanced formulation of
amoxicillin ⁄ clavulanate against both S. pneumoniae
and Haemophilus inﬂuenzae. Their kinetic model
uses a ﬁlter to prevent elimination of the bacteria
when antibiotic concentrations are reduced by
dilution with fresh media. They studied 12-hourly
dosing of the new formulation for 24 h against
four strains of S. pneumoniae that had amoxicillin
MICs of 1, 2, 4 and 8 mg ⁄L. The starting inoculum
was approximately 106 colony-forming units
(CFU) ⁄mL. The new formulation completely
eradicated the strains with MICs of 1 and
2 mg ⁄L, however regrowth followed the initial
killing of the organisms with MICs of 4 and
8 mg ⁄L. At 24 h the new formulation reduced the
CFUs of the organism with a MIC of 4 mg ⁄L by
several logs, but was only bacteriostatic against
the most resistant strain.
In their studies with two strains of H. inﬂuenzae,
Lo¨wdin, Cars and Odenholt [10] compared the
activity of pharmacokinetically enhanced amoxi-
cillin ⁄ clavulanate 2000 ⁄ 125 mg twice daily with
that of conventional amoxicillin ⁄ clavulanate
500 ⁄ 125 mg three times daily and 875 ⁄ 125 mg
twice daily. They observed that three times daily
administration of 500 ⁄ 125 mg of the drug tended
to give a greater bactericidal effect than observed
with 875 ⁄ 125 mg twice daily. On the other hand,
the pharmacokinetically enhanced formulation
produced a statistically higher bactericidal effect
than with the other two dosing regimens, and
resulted in complete killing of both strains by
24 h.
MacGowan and associates [12,13] have used a
slightly different in-vitro kinetic model to study
the activity of various antimicrobials against
strains of S. pneumoniae. The model is a dilution
kinetic model that can dilute both the drug and
the organism being studied. Their studies on the
activity of twice-daily dosing of pharmacokinet-
ically enhanced amoxicillin ⁄ clavulanate used
seven strains of S. pneumoniae with MICs of
4–8 mg ⁄L at two different inocula (106 and 108
CFU ⁄mL). They observed rapid bactericidal activ-
ity with all strains at both inocula. At the high
inoculum, however, one strain with an MIC of
8 mg ⁄L was associated with regrowth after 12 h
that was due to the emergence of a more resistant
organism. A summary of the results at 2, 4, 6, 12
and 24 h with all seven organisms at the high
inocula is illustrated in Figure 1. It is important to
remember that these in-vitro kinetic models
measure antimicrobial activity without the inﬂu-
ence of host immune factors, such as polymor-
phonuclear leukocytes and complement. In-vitro
studies using polymorphonuclear leukocytes and
complement have demonstrated increased bacte-
ricidal activity of the aminopenicillins against
S. pneumoniae [14].
ANIMAL INFECTION MODELS
A variety of animal studies have already evalu-
ated the efﬁcacy of amoxicillin and ⁄ or amoxicil-
lin ⁄ clavulanate at 500 ⁄ 125 mg and 1000 ⁄ 125 mg
three times daily and 875 ⁄ 125 mg twice daily,
Craig Performance testing in models 13
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10 (Suppl. 2), 12–17
and paediatric formulations of 45 ⁄ 6.4 and
90 ⁄ 6.4 mg ⁄ kg ⁄day in two divided doses [6,15–
17]. Human pharmacokinetics were simulated in
these studies either by computer-coordinated
drug infusion through intravenous catheters or
by inducing renal impairment with the prior
administration of uranyl nitrate [18]. These stud-
ies suggested that the lower doses were effective
against pneumococci with MICs up to 2 mg ⁄L.
The higher doses, such as 1000 ⁄ 125 mg three
times daily and 90 ⁄ 6.4 mg ⁄ kg ⁄day in two divided
doses, were active against organisms with MICs
up to 4 mg ⁄L. Berry [19] also compared the
activity of pharmacokinetically enhanced amoxi-
cillin ⁄ clavulanate with more traditional dosing
regimens and other drugs in a rat pneumonia
model infected with strains of S. pneumoniae with
MICs of 4 and 8 mg ⁄L. These studies involved six
of the seven strains studied by Noel, MacGowan
and Bowker in the in-vitro kinetic model [13].
Infection in this model is induced by direct
intrabronchial instillation of a 100 lL bacterial
inoculum in cooled molten agar. Drug dosing was
started 24 h post infection and was continued for
3 days. The drugs and doses simulated through
computer-controlled intravenous infusion inclu-
ded pharmacokinetically enhanced amoxicil-
lin ⁄ clavulanate at 2000 ⁄ 125 mg twice daily,
conventional immediate-release amoxicillin ⁄ cla-
vulanate at 875 ⁄ 125 and 1000 ⁄ 125 mg three times
daily and 875 ⁄ 125 mg twice daily, levoﬂoxacin at
500 mg once daily, and azithromycin at 1000 mg
initially followed by 500 mg once daily. The
serum concentrations obtained in this animal
model were very similar to those obtained in
humans (see Figure 2 for pharmacokinetically
enhanced amoxicillin ⁄ clavulanate). Animals
were euthanized at 14 h after cessation of ther-
apy. The lungs were removed and homogenised,
and serial dilutions were plated for CFU deter-
minations.
Bacterial numbers in the control animals var-
ied from 5.7 to 7.1 log10 CFU ⁄ lungs with a mean
value of 6.3 log10 CFU ⁄ lungs. The difference
between controls and the animals treated with
different dosage regimens of conventional and
pharmacokinetically enhanced amoxicillin ⁄ cla-
vulanate are illustrated in Fig. 3(a) for pneumo-
coccal strains with MICs of 4 mg ⁄L and Fig. 3(b)
for strains with MICs of 8 mg ⁄L. The variation in
bacterial numbers among the different animals
was relatively small as standard deviations
ranged from 0.6 to 1.4 log10 CFU ⁄ lungs.
With the three strains of S. pneumoniae with
MICs of 4 mg ⁄L, pharmacokinetically enhanced
amoxicillin ⁄ clavulanate at 2000 ⁄ 125 mg twice
daily and conventional amoxicillin ⁄ clavulanate
at 875 ⁄ 125 and 1000 ⁄ 125 mg three times daily
gave signiﬁcantly better results than conventional
amoxicillin ⁄ clavulanate at 875 ⁄ 125 mg twice daily.
With the three strains that had MICs of 8 mg ⁄L,
only the pharmacokinetically enhanced formula-
tion of amoxicillin ⁄ clavulanate markedly reduced
Fig. 2. Plasma concentrations of pharmacokinetically
enhanced amoxicillin (AMX) ⁄ clavulanate (CLA) in
humans and simulated values in rats. Data obtained from
reference 19.
Fig. 1. Bacterial kill curves for seven strains of S. pneumo-
niae following exposure to simulated concentrations of
pharmacokinetically enhanced amoxicillin ⁄ clavulanate in
an in-vitro kinetic model. Figure redrawn from data in
reference 13.
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the number of organisms remaining in the lungs
after 3 days of therapy.
A comparison of the efﬁcacy of the pharma-
cokinetically enhanced amoxicillin ⁄ clavulanate at
2000 ⁄ 125 mg twice daily with levoﬂoxacin at
500 mg once daily and azithromycin at 1000 mg
followed by 500 mg once daily are shown in
Fig. 4(a,b) for strains with MICs of 4 and
8 mg ⁄L, respectively. Four of the ﬁve strains
studied with azithromycin were macrolide resist-
ant. Azithromycin showed minimal killing with
these strains. Azithromycin was highly active
against the one susceptible strain resulting in a
3.3 log10 reduction in CFU ⁄ lungs. Although
levoﬂoxacin was active against all strains, the
degree of killing was rather modest for the three
strains with amoxicillin MICs of 4 mg ⁄L. Phar-
macokinetically enhanced amoxicillin ⁄ clavula-
nate was statistically more effective than
levoﬂoxacin against these strains, and was sta-
tistically more effective against one of the three
pneumococcal strains with the highest amoxicil-
lin MICs.
CORRELATION OF OUTCOME WITH
TIME ABOVE MIC
Previous animal studies that have used dose
fractionation to reduce the interrelationship
between different pharmacokinetic ⁄pharmaco-
dynamic (PK ⁄PD) parameters, have clearly
(a)
(b)
Fig. 4. Reduction in log10 CFU ⁄ lungs compared with con-
trols with pharmacokinetically enhanced amoxicillin ⁄
clavulanate, levoﬂoxacin and azithromycin against: (a)
S. pneumoniae strainswithMICs of 4 mg ⁄L; (b) S. pneumoniae




Fig. 3. Reduction in log10 CFU ⁄ lungs compared with
controls with pharmacokinetically enhanced amoxicillin ⁄
clavulanate and three other dosing regimens of conven-
tional amoxicillin ⁄ clavulanate against: (a) S. pneumoniae
strains with MICs of 4 mg ⁄L; (b) S. pneumoniae strains with
MICs of 8 mg ⁄L. Data obtained from reference 19.
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demonstrated that time above MIC (T > MIC) is
the important PK ⁄PD parameter for determining
the efﬁcacy of b-lactam antimicrobials [20–22].
Speciﬁc studies with amoxicillin and amoxicil-
lin ⁄ clavulanate have suggested that maximal
activity is observed when serum concentrations
exceed the MIC for 35–40% of the dosing interval
[6,15,16]. Very similar values have been observed
using both thigh and lung infection models [23].
Fig. 5 illustrates the relationship between
T >MIC and the reduction in log10 CFU ⁄ lungs
observed with the different formulations of amox-
icillin ⁄ clavulanate against the various strains
shown in Fig. 3(a,b). The curved line represents
the best-ﬁt line by nonlinear regression using a
maximum effect model [24]. The correlation of
activity with T >MIC was very strong, with 84%
of the variation being attributed to T > MIC. It
appears that with the strains studied, killing of
2.5–3 log10 CFU ⁄ lungs requires a T > MIC of 35%,
and that maximum killing occurs when amoxicil-
lin ⁄ clavulanate serum concentrations are above
the MIC for 40% of the dosing interval. Noel,
MacGowan and Bowker [13] also looked at the
relationship between T > MIC and killing of these
same pneumococci in their in-vitro kinetic model.
They not only evaluated pharmacokinetically
enhanced amoxicillin ⁄ clavulanate at 2000 ⁄ 125 mg
twice daily, but also determined the extent of
killing at doses that were half and a quarter of the
standard dose. They also observed that maximum
killing of these pneumococci occurred when
concentrations in their in-vitro model exceeded
the MIC for 40% of the dosing interval.
CONCLUSIONS
These studies provide further support to the
PK ⁄PD principles that indicate that a T > MIC
of 35–40% of the dosing interval for amoxicillin
and amoxicillin ⁄ clavulanate is predictive of
high bactericidal efﬁcacy. Pharmacokinetically
enhanced amoxicillin ⁄ clavulanate was developed
using these principles to increase efﬁcacy against
strains of S. pneumoniae with amoxicillin ± clavul-
anate MICs of 4 and 8 mg ⁄L. The in-vitro kinetic
and animal model studies reviewed suggest that
this formulation will be very effective in patients.
The ﬁnal proof of these PD principles can only be
demonstrated in prospective comparative clinical
trials.
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